RecruitingPhase 2NCT05587712
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Sotatercept(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 1-17 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606), Los Angeles, California, United States
- Stanford University School of Medicine ( Site 1603), Palo Alto, California, United States
- UCSF Benioff Children's Hospital San Francisco ( Site 1611), San Francisco, California, United States
- Children's Hospital Colorado ( Site 1609), Aurora, Colorado, United States
- Children's National Medical Center ( Site 1600), Washington D.C., District of Columbia, United States
- Cincinnati Children's Hospital Medical Center ( Site 1602), Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia (CHOP) ( Site 1608), Philadelphia, Pennsylvania, United States
- Monroe Carell Jr. Children's Hospital ( Site 1601), Nashville, Tennessee, United States
- Seattle Children's Hospital ( Site 1605), Seattle, Washington, United States
- Children's Wisconsin ( Site 1610), Milwaukee, Wisconsin, United States
- The Children's Hospital at Westmead ( Site 0001), Westmead, New South Wales, Australia
- Clinica Somer-Unidad de Investigacion y Docencia ( Site 0205), Rionegro, Antioquia, Colombia
- Fundación Valle del Lili ( Site 0200), Cali, Valle del Cauca Department, Colombia
- Clínica Imbanaco S.A.S ( Site 0203), Cali, Valle del Cauca Department, Colombia
- CHU de Toulouse - Hôpital des Enfants ( Site 0302), Toulouse, Haute-Garonne, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05587712 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →